Affiliation:
1. Hospital Clínico San Carlos, Madrid, Spain
2. Hospital 12 de Octubre, Madrid, Spain
3. Hospital Niño Jesús, Madrid, Spain
4. Hospital La Paz, Madrid, Spain
5. Hospital Gregorio Marañón and CIBER of Respiratory Diseases, CIBERES, Madrid, Spain
Abstract
ABSTRACT
To assess invasive pneumococcal disease (IPD) clinical presentations and relationships with age and serotype in hospitalized children (<15 years) after PCV7 implementation in Madrid, Spain, a prospective 2-year (May 2007 to April 2009) laboratory-confirmed (culture and/or PCR) IPD surveillance study was performed (22 hospitals). All isolates (for serotyping) and culture-negative pleural/cerebrospinal fluids were sent to the reference laboratory for pneumolysin (
ply
) and autolysin (
lyt
) gene PCR analysis. A total of 330 IPDs were identified: 263 (79.7%) confirmed by culture and 67 (20.3%) confirmed by PCR. IPD distribution by age (months) was as follows: 23.6% (<12), 15.8% (12 to 23), 15.5% (24 to 35), 22.4% (36 to 59), and 22.7% (>59). Distribution by clinical presentation was as follows: 34.5% bacteremic pneumonia, 30.3% pediatric parapneumonic empyema (PPE), 13.6% meningitis, 13.3% primary bacteremia, and 8.2% others. Meningitis and primary bacteremia were the most frequent IPDs in children <12 months old, and bacteremic pneumonia and PPE were most frequent in those >36 months old. Frequencies of IPD-associated serotypes were as follows: 1, 26.1%; 19A, 18.8%; 5, 15.5%; 7F, 8.5%; 3, 3.9%; nontypeable/other 30 serotypes, 27.3%. Serotype 1 was linked to respiratory-associated IPD (38.6% in bacteremic pneumonia and 38.0% in PPE) and children of >36 months (51.4% for 36 to 59 months and 40.0% for >59 months), while serotype 19A was linked to nonrespiratory IPDs (31.1% in meningitis, 27.3% in primary bacteremia, and 51.9% in others) and children of <24 months (35.9% for children of <12 months and 36.5% for those 12 to 23 months old), with high nonsusceptibility rates for penicillin, cefotaxime, and erythromycin. After PCV7 implementation, non-PCV7 serotypes caused 95.5% of IPDs. The new 13-valent conjugate vaccine would provide 79.1% coverage of serotypes responsible for IPDs in this series.
Publisher
American Society for Microbiology
Subject
Microbiology (medical),Clinical Biochemistry,Immunology,Immunology and Allergy
Reference28 articles.
1. Austrian, R. 1997. The enduring pneumococcus: unfinished business and opportunities for the future. Microb. Drug Resist. 3:111-115.
2. Barricarte, A., A. Gil-Setas, L. Torroba, J. Castilla, A. Petit, I. Polo, M. Arriazu, F. Irisarri, and M. García Cenoz. 2007. Invasive pneumococcal disease in children younger than 5 years in Navarra, Spain (2000-2005). Impact of the conjugate vaccine. Med. Clin. (Barc). 129:41-45. (In Spanish.)
3. Centers for Disease Control and Prevention. 2005. Direct and indirect effects of routine vaccination of children with 7-valent pneumococcal conjugate vaccine on incidence of invasive pneumococcal disease—-United States, 1998-2003. MMWR Morb. Mortal. Wkly. Rep. 54:893-897.
4. Centers for Disease Control and Prevention. 2008. Invasive pneumococcal disease in children 5 years after conjugate vaccine introduction—-eight states, 1998-2005. MMWR Morb. Mortal. Wkly. Rep. 57:144-148.
5. Centers for Disease Control and Prevention. 2010. Invasive pneumococcal disease in young children before licensure of 13-valent pneumococcal conjugate vaccine—United States, 2007. MMWR Morb. Mortal. Wkly. Rep. 59:253-257.